XNCR ▼ -1.1% - Xencor, Inc. $XNCR - Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors 25-OCT-2026 04:37 AM ET